KERENDIA Market

“KERENDIA Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about KERENDIA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) in the seven major markets. A detailed picture of the KERENDIA in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the KERENDIA. The report provides insights about KERENDIA mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KERENDIA market forecast analysis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies.

KERENDIA Drug Summary

KERENDIA (finerenone/BAY 94-8862) is a novel, first-in-class nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block harmful effects of mineralocorticoid receptor (MR) overactivation. In type 2 diabetes (T2D), MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage, which metabolic, hemodynamic, or inflammation and fibrosis factors can drive. The drug is indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, nonfatal myocardial infarction (MI), and hospitalization for heart failure in adult patients with CKD associated with T2D. 

KERENDIA Dosage and administration 

The recommended starting dose of KERENDIA is based on eGFR. 

• eGFR (mL/min/1.73m2 ) ≥60: 20 mg once daily 
• eGFR (mL/min/1.73m2 ) ≥25 to <60: 10 mg once daily
• eGFR (mL/min/1.73m2 ) <25: Initiation is not recommended 

KERENDIA Market Report Scope

The report provides insights into:

• A comprehensive product overview including the KERENDIA description, KERENDIA mechanism of action, dosage and administration, research and development activities in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD).
• Elaborated details on KERENDIA regulatory milestones and other development activities have been provided in this report.
• The KERENDIA Market Forecast Report also highlights the KERENDIA research and development activities in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) across the United States, Europe, and Japan.
• The KERENDIA Market Forecast Report also covers the patent information with expiry timeline around KERENDIA.
• The report contains forecasted KERENDIA Sales for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) till 2032.
• Comprehensive coverage of the late-stage Chronic Kidney Disease Emerging Therapies and Diabetic Kidney Disease (DKD).
• The report also features the SWOT analysis with analyst views for KERENDIA in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD).

KERENDIA Methodology

The KERENDIA Market Report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and KERENDIA Sales Data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KERENDIA Market Analytical Perspective by DelveInsight

• In-depth KERENDIA Market Assessment

This report provides a detailed market assessment of KERENDIA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted KERENDIA Sales Data from 2025 to 2032.

• KERENDIA Clinical Trials Assessment

The report provides the KERENDIA Clinical Trials information for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) covering trial interventions, trial conditions, trial status, start and completion dates.

KERENDIA Market Forecast Report Highlights  

• In the coming years, the market scenario for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The KERENDIA Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KERENDIA dominance.
• Other emerging KERENDIA Products for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) are expected to give tough market competition to KERENDIA and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KERENDIA in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD).
• Our in-depth analysis of the forecasted sales data of KERENDIA from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KERENDIA in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD). 
• Analyze KERENDIA Cost, pricing trends, and market positioning to support strategic decision-making in the KERENDIA Market Landscape

Key Questions

• What is the KERENDIA Product Type, route of administration and KERENDIA mechanism of action?
• What is the KERENDIA Clinical Trials status of the study related to KERENDIA in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KERENDIA development?
• What are the key designations that have been granted to KERENDIA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)?
• What is the forecasted market scenario of KERENDIA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)?
• What are the forecasted KERENDIA Sales in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging KERENDIA Products available, and how are these giving competition to KERENDIA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)?
• Which are the late-stage emerging therapies under development for the treatment of Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)?

Stay updated with us for Recent Articles @ Latest DelveInsight Blogs